Recombinant Human BCL2 Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-0367

Recombinant Human BCL2 Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-0367
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession P10415
Synonym Bcl-2, PPP1R50
Background BCL2 (B-cell leukemia/lymphoma 2, N-Histidine-tagged), also known as Bcl-2, belongs to the Bcl-2 family. Bcl-2 family proteins regulate and contribute to programmed cell death or apoptosis. It is a large protein family and all members contain at least one of four BH (bcl-2 homology) domains. Certain members such as Bcl-2, Bcl-xl and Mcl1 are anti-apoptotic, whilst others are pro-apoptotic. Most Bcl-2 family members contain a C-terminal transmembrane domain that functions to target these proteins to the outer mitochondrial and other intracellular membranes. It is expressed in a variety of tissues. BCL2 blocks the apoptotic death of some cells such as lymphocytes. It also regulates cell death by controlling the mitochondrial membrane permeability and inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy
Description A DNA sequence encoding the human BCL2 isoform 1 (P10415-) (Met 1-Asp 211) was expressed, with a His tag at the C-terminus.
Source E.coli
Predicted N Terminal Met 1
AA Sequence Met 1-Asp 211
Molecular Weight The recombinant human BCL2 consisting of 221 a.a. and has a calculated molecular mass of 24.7 kDa. It migrates as an approximately 32 KDa band in SDS-PAGE under reducing conditions.
Purity >90% as determined by SDS-PAGE
Endotoxin Please contact us for more information.
Bioactivity Measured by its binding ability in a functional ELISA. Immobilized human BCL2-His at 10 ug/ml (100 ul/well) can bind biotinylated mouse BCL2L1-His, The EC50 of biotinylated mouse BCL2L1-His is 0.07-0.15 ug/ml.
Formulation Lyophilized from sterile 50mM Tris, 20% glycerol, 100mM Arg, pH 8.5.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). Also acts as an inhibitor of autophagy: interacts with BECN1 and AMBRA1 during non-starvation conditions and inhibits their autophagy function. May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release.
Subcellular Location Mitochondrion outer membrane; Single-pass membrane protein. Nucleus membrane; Single-pass membrane protein. Endoplasmic reticulum membrane; Single-pass membrane protein.
Protein Families Bcl-2 family
Database References
Associated Diseases A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
Tissue Specificity Expressed in a variety of tissues.

Gene Functions References

  1. long noncoding RNA HOTAIR suppresses TNF-alpha induced nucleus pulposus cell apoptosis by regulating miR-34a/Bcl-2 axis. PMID: 30138895
  2. The mitochondrial depolarization also stems from the Bcl-2 inhibition mediated by DFMT, followed by the cytochrome c release that activates caspase signaling. With the participation of the two-pronged mechanism, a programmed apoptosis is induced in response to DFMT treatment. PMID: 28805013
  3. miR-7-5p reduced energy consumption via inhibiting PARP-1 expression, and miR-7-5p increased energy generation by suppressing the expression of Bcl-2. PMID: 30219819
  4. Venetoclax-based combination treatment for newly diagnosed elderly patients for whom intense chemotherapy is not an option may be the first setting in which this agent may be employed in Acute myeloid leukemia. Based on pre-clinical evidence, BCL-2 inhibition may be useful in relapsed/refractory disease in conjunction with cytotoxic therapy, but has modest single agent activity. PMID: 29264938
  5. Glandular, menopause-independent DFF40, DFF45, and Bcl-2 overexpression may play an important role in the pathogenesis of endometrial polyps and benign endometrial hyperplasia PMID: 28914671
  6. data strongly suggest that XIAP-mediated inhibition of final caspase-3 processing is the last and major hurdle in TRAIL-induced apoptosis in NCI-H460 cells, which can be overcome by Smac in a Bcl-2 level dependent manner. PMID: 29927992
  7. could not find any relationship between Bcl-2, c-Myc and EBER-ISH positivity and the low/high IPS groups in classical Hodgkin lymphoma PMID: 29708579
  8. Fluorescence in situ hybridization studies (histologic sections) confirmed translocations of MYC (8q24), BCL2 (18q21) and BCL6 (3q27) in all patients. PMID: 30043475
  9. High BCL-2 expression is associated with colorectal cancer. PMID: 30015962
  10. MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression. PMID: 29914005
  11. Results revealed that BCL-2 protein is highly expressed in colon cancer tissues and was identified as a direct target for mir-184. BCL-2 appeared to participate in cell cycle regulation and malignant transformation to colon cancer. PMID: 28782841
  12. Results indicate that full-length B-cell leukemia 2 family protein (Bcl-2) Ile14Gly/Val15Gly displayed severely reduced structural stability and a shortened protein half-life. PMID: 29131545
  13. Data show the regulation of BCL2 mainly associated with methylation across the molecular subtypes of breast cancer. Luminal A and B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with better prognosis than downregulation of BCL2. PMID: 28701032
  14. c-MYC/BCL2 protein co-expression in non-germinal center B-cell subtype constituted a unique group with extremely inferior outcome regardless of ethnicity PMID: 29801406
  15. Overexpression of LIN28B promotes colon cancer development by increasing BCL-2 expression. PMID: 29669301
  16. High BCL2 expression is associated with Prostate Cancer. PMID: 29641255
  17. The findings of the present study indicated that icariin prevented injury and apoptosis in HUVECs following oxLDL treatment, in particular via the regulation of protein and mRNA expression levels of Bcl-2 and caspase-3. PMID: 29532884
  18. BCL2 expression is also a strong predictive marker for DLBCL patients treated with R-CHOP. PMID: 28154089
  19. High BCL2 expression is associated with drug resistance in ovarian cancer. PMID: 29286126
  20. Elevated expression of Bcl-2 was an independent prognostic factor for poorer overall survival in triple-negative breast cancer and as such a significant marker for tumor aggressiveness. PMID: 28777433
  21. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression. PMID: 29666157
  22. Phosphorylated and activated deoxycytidine kinase inhibits ionizing radiation (IR)-induced total cell death and apoptosis, and promotes IR-induced autophagy through the mTOR pathway and by inhibiting the binding of Bcl2 protein to BECN1 in breast cancer cells. PMID: 29393406
  23. It was demonstrated that hypoxia stimulates migration and invasion in the MG63 human osteosarcoma cell line, which was correlated with the downregulation of miR15a and upregulation of B-cell lymphoma 2 (Bcl2) expression PMID: 29484432
  24. miR-21 may promote salivary adenoid cystic carcinoma progression via PDCD4 and PTEN down-regulation and Bcl-2 up-regulation. PMID: 29328455
  25. Paper analyses results of serum cytokines and lymphocyte apoptosis study in nodular goiter against the background of autoimmune thyroiditis and thyroid adenoma based on the cell preparedness to apoptosis, the number of apoptotic lymphocytes and the content of proapoptotic tumor necrosis factor-alpha, interleukins in serum, considering the polymorphism of BCL-2, CTLA-4 and APO-1 genes. PMID: 29250672
  26. Permeabilisation of the mitochondrial outer membrane (MOMP) is directly regulated by the BCL-2 (B cell lymphoma 2) family in mammals [Review]. PMID: 28396106
  27. The present study demonstrated that TATfused inositol 1,4,5trisphosphate receptorderived peptide (TATIDPS), which targets the BH4 domain of Bcl2, increased cisplatininduced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. PMID: 29207009
  28. we highlight the emerging recognition of MYC and BCL2 coexpression as the most robust predictor of diffuse large B cell lymphoma outcome, and discuss rationally conceived experimental approaches to treat these high-risk patients. PMID: 29198442
  29. Bcl-2 binding to ARTS involves the BH3 domain of Bcl-2. Lysine 17 in Bcl-2 serves as the main acceptor for ubiquitylation, and a Bcl-2 K17A mutant has increased stability and is more potent in protection against apoptosis. PMID: 29020630
  30. The expression levels of miR-204-5p were downregulated in prostate cancer cells compared with normal prostate epithelial cells. BCL2 mRNA and protein expression decreased in miR-204-5p-transfected cells, which led to cytochrome C release from mitochondria. Cotransfection of a reporter vector harboring the BCL2 3'-untranslated region to compete with endogenous transcripts partially rescued miR-204-5p-induced apoptosis. PMID: 27519795
  31. GATA4 was a transcription factor that activated mouse double minute 2 homolog (MDM2) and B cell lymphoma 2 (BCL2) expression in ALL cells. PMID: 28849107
  32. High BCL2 expression is associated with oncogenicity and chemoresistance in hepatocellular carcinoma. PMID: 28445151
  33. Gastrin and BCL2 apoptosis regulator (Bcl2) are highly expressed in gastric cancer tissues, and they are correlated with the clinicopathologic features. PMID: 29268861
  34. This study utilized a lentiviral vector that overexpressed the human VEGF and Bcl-2 genes simultaneously. Co-overexpression of VEGF and Bcl-2 inhibits the oxygen glucose deprivation induced apoptosis of mesenchymal stem cells. PMID: 28627637
  35. Double-hit lymphoma (DHL) is an aggressive form of DLBCL with an unmet treatment need, in which MYC rearrangement is present with either BCL2 or BCL6 rearrangement PMID: 28952038
  36. The expression of Bcl-2 and E cadherin immunopositivity was associated positively with tumor grade, high T category and histopathological grades. The results of this study points to the significance of cell proliferation and invasion as a major determinant of prognosis in OSCC. PMID: 28393810
  37. meta-analysis suggests a role BCL-2 promoter polymorphisms in cancer susceptibility and prognosis; rs2279115 was associated with higher risk of cancer susceptibility in Asia but not in Caucasian; rs2279115 was associated with a higher risk in digestive system cancer and endocrine system cancer but not breast cancer, respiratory cancer and hematopoietic cancer PMID: 28445963
  38. In this study, we investigated whether APG-1252-12A inhibits the growth of five leukemia cell lines in a concentration- or time-dependent manner by MTS assay.APG-1252-12A is a Bcl-2 homology (BH)-3 mimetic that specifically binds to Bcl-2 and Bcl-xl, which has shown efficacy in some Bcl-2 dependent hematological cancers PMID: 28586007
  39. Multiple lines of evidence suggest formation of a potential cruciform DNA structure at MBR peak III, which was also supported by in silico studies. The formation of a non-B DNA structure could be a basis for fragility at BCL2 breakpoint regions, eventually leading to chromosomal translocations. PMID: 29246583
  40. The upregulation of miR-219-5p inhibited melanoma growth and metastasis and strengthened melanoma cells chemosensitivity by targeting Bcl-2. Therefore, the modulation of miR-219-5p expression may be a novel treatment strategy in melanoma. PMID: 28884131
  41. The expression of the anti-apoptotic protein Bcl-2 was greater in luminal A breast cancer tissue samples compared to triple-negative breast cancer. PMID: 28801774
  42. Lnc_ASNR interacted with the protein ARE/poly (U)-binding/degradation factor 1(AUF1), which is reported to promote rapid degradation of the Bcl-2 mRNA, an inhibitor of apoptosis. Lnc_ASNR binds to AUFI in nucleus, decreasing the cytoplasmic proportion of AUF1 which targets the B-cell lymphoma-2 (Bcl-2) mRNA. PMID: 27578251
  43. Bcl-2 high expression was significantly correlated with favorable overall survival and better disease/recurrence free survival in colorectal cancer.[meta-analysis] PMID: 28785155
  44. High expression of bcl-2 in KCOT supports the general agreement that some features of KCOT are those of a neoplasia. The bcl-2 expression in connective tissue cells suggests that these cells may also be important as epithelial cells in the biological behavior odontogenic keratocyst PMID: 28862228
  45. Results identified BCL2 as a direct target of miR-139-5p in colorectal cancer cells and showed that the tumor suppressor activity of miR-139-5p is mediated by the modulation of BCL2 expression. PMID: 27244080
  46. Polo-like kinase inhibition can sensitize cholangiocarcinoma cells to cisplatin-induced apoptosis with proteasomal Bcl-2 degradation as an additional pro-apoptotic effect. PMID: 28652654
  47. Lipid oxidation product 4-hydroxy-2-nonenal is at the crossroads of NF-kappaB pathway and anti-apoptotic Bcl2 expression. (Review) PMID: 27840321
  48. Ibrutinib-resistant TMD8 cells had higher BCL2 gene expression and increased sensitivity to ABT-199, a BCL-2 inhibitor. Consistently, clinical samples from ABC-DLBCL patients who experienced poorer response to ibrutinib had higher BCL2 gene expression. We further demonstrated synergistic growth suppression by ibrutinib and ABT-199 in multiple ABC-DLBCL, GCB-DLBCL, and follicular lymphoma cell lines. PMID: 28428442
  49. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors PMID: 27217294
  50. The BCL2 c.-938C>A and c.21G>A single-nucleotide polymorphisms showed a significant impact on outcome with transitional cell carcinoma of the bladder PMID: 28417194


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed